Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations (2016 - 2025)

Ocular Therapeutix has reported Cash from Operations over the past 13 years, most recently at 54249000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 54249000.0 for Q4 2025, down 37.59% from a year ago — trailing twelve months through Dec 2025 was 204883000.0 (down 52.13% YoY), and the annual figure for FY2025 was 204883000.0, down 52.13%.
  • Cash from Operations for Q4 2025 was 54249000.0 at Ocular Therapeutix, down from 50725000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for OCUL hit a ceiling of 7732000.0 in Q3 2023 and a floor of 55238000.0 in Q2 2025.
  • Median Cash from Operations over the past 5 years was 20065500.0 (2021), compared with a mean of 26747350.0.
  • Biggest five-year swings in Cash from Operations: surged 45.77% in 2022 and later plummeted 372.83% in 2024.
  • Ocular Therapeutix's Cash from Operations stood at 15153000.0 in 2021, then dropped by 11.91% to 16958000.0 in 2022, then tumbled by 32.41% to 22454000.0 in 2023, then crashed by 75.6% to 39429000.0 in 2024, then crashed by 37.59% to 54249000.0 in 2025.
  • The last three reported values for Cash from Operations were 54249000.0 (Q4 2025), 50725000.0 (Q3 2025), and 55238000.0 (Q2 2025) per Business Quant data.